Prostate Cancer

Darolutamide plus androgen deprivation therapy and docetaxel was not associated with an increase in incidence or severity of adverse events versus androgen deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Data supporting prostate-specific antigen screening shows harm-benefit tradeoff to be more favorable with complementary approaches to quantifying overdiagnosis.

The safety profile of relugolix in patients with advanced prostate cancer has been demonstrated in the phase 3 HERO clinical trial.

Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Findings from a post-hoc analysis of the phase 3 ARAMIS clinical trial shows positive efficacy and consistent safety and tolerability with darolutamide in patients with nonmetastatic castration resistant prostate cancer, despite type of prior local therapy.

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.

Use of 18F-rhPSMA-7.3 PET results in post-scan upstaging compared with conventional imaging in patients with prostate cancer recurrence.

Production of lutetium Lu 177 vipivotide tetraxetan and Luthathera have been temporarily suspended due to potential quality issues identified in their manufacturing processes.

The FDA has accepted a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review.

Tanya Dorff, MD, discusses the recent findings from a phase 1 clinical trial which explored the use of chimeric antigen receptor T-cell therapy in patients with prostate cancer.

Results from the phase 3 ARCHES trial confirm the survival benefit of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

A recent study looked into where time-to-next therapy and overall survival with immune checkpoint inhibitors were longer compared with taxane therapy, in patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.

Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.

An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

A discussion of key safety data on the VISION trial.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

A comprehensive review of treatment options for metastatic prostate cancer, including PSMA-targeted therapies.

Scott Tagawa, MD, MS, FACP expands upon prostate-specific membrane antigen (PSMA)-based PET imaging modalities.

A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.